troglitazone has been researched along with isoxazoles in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsui, K; Nagao, K; Shibata, T; Shinkai, H; Wakitani, K; Yonemori, F | 1 |
| Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y | 1 |
| Epstein, RA | 1 |
| Goda, K; Kobayashi, A; Kuno, H; Shoda, T; Sugai, S; Takahashi, T | 1 |
6 other study(ies) available for troglitazone and isoxazoles
| Article | Year |
|---|---|
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Isoxazoles; Male; Mice; Mice, Inbred Strains; Oxidation-Reduction; Pioglitazone; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1999 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chromans; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Neuropathies; Eating; Hypoglycemic Agents; Isoxazoles; Male; Neural Conduction; Obesity; Pancreas; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone | 2000 |
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2000 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans; Hypoglycemic Agents; Isoxazoles; Lactones; Myocardial Infarction; Paternalism; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Thiazolidinediones; Troglitazone; Truth Disclosure; United States; United States Food and Drug Administration; Vasodilator Agents | 2005 |
Usefulness of in vitro combination assays of mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury.
Topics: Acetaminophen; Apoptosis; Biological Assay; Biomarkers; Caspase 3; Caspase 7; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chromans; Diclofenac; Dose-Response Relationship, Drug; Ethanol; Hepatocytes; Humans; Isoxazoles; Leflunomide; Liver; Mitochondria, Liver; Oxygen Consumption; Primary Cell Culture; Ranitidine; Risk Assessment; Thiazolidinediones; Time Factors; Toxicity Tests; Troglitazone | 2016 |